Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 3Suspended 2Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 28Magnetic Resonance Spectroscopy 19Biopsy 18Cyclophosphamide 7venetoclax 5Vincristine 5Bevacizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3decitabine and cedazuridine drug combination 3X-Rays 3Taxes 3Radiosurgery 3Radiation 3Prednisone 3Injections 3Doxorubicin 3Cetuximab 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2fludarabine 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × (225)Ac-DOTA-c(RGDyK) × 90 days × Clear all
NCT06102902 2026-06-03

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡